Previous 10 | Next 10 |
Results show a pre-treatment with a micro dose (150 µg) of Gvoke RTU Micro significantly prevented Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high intensity aerobic exercise in a real-world setting with or without adjustment to insulin Study achieved all pri...
Xeris Pharmaceuticals (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today reported encouraging findings from the outpatient stage of a Phase 2 proof-...
Rebound hypoglycemia observed in the placebo arm with oral glucose tablet use; No rebound hypoglycemia observed in the RTU glucagon treatment arm Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation platforms to develop and com...
Xeris Pharmaceuticals ( XERS -6.4% ) enters into a non-exclusive agreement with unlicensed medicine distributor Clinigen Group plc for the supply and distribution of Gvoke (glucagon injection) outside of the U.S. on a "named patient" basis while its marketing application in Europe is und...
Xeris Pharmaceuticals (NASDAQ: XERS ) announces an exclusive agreement with Clinigen Group to manage the supply and distribution of Gvoke outside of U.S. where Gvoke is not currently licensed. More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced an exclusive agreement with Clinigen Group plc (AIM: CLIN,...
SIFCO (NYSEMKT: SIF ) +61% on Q2 results . More news on: SIFCO Industries, Inc., United Natural Foods, Inc., Cyclacel Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Image source: The Motley Fool. Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) Q1 2020 Earnings Call May 9, 2020 , 8:30 p.m. ET Operator Continue reading
Xeris Pharmaceuticals, Inc. (XERS) Q1 2020 Earnings Conference Call May 7, 2020 8:30 AM ET Company Participants Allison Wey – Senior Vice President-Investor Relations and Corporate Communication Paul Edick – Chairman and Chief Executive Officer Barry Deutsch –...
Xeris Pharmaceuticals (NASDAQ: XERS ): Q1 GAAP EPS of -$0.89 misses by $0.05 . More news on: Xeris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...